Henning is a senior executive and entrepreneur with more than 20 years of operational experience in Pharma, Biotech and Venture capital. Henning co-founded Lario Therapeutics in Nov 2021 and is leading the company as CEO. He is also acting as Venture Partner at Epidarex Capital and co-founder and CEO of Epidarex Exeed, the therapeutic engine of Epidarex.
Henning currently serves on the Boards of Directors of Lario Therapeutics Ltd, Epidarex Exeed Ltd, Caldan Therapeutics Ltd, Theolytics Ltd and Libra Therapeutics Inc.
Previously, Henning served as President R&D at Aptuit, a leading R&D organization. As a member of the executive team he led the growth and transformation including a successful $300m private equity exit. Prior to that he acted as SVP and Head of Global Drug Discovery at Grünenthal and held senior roles at Sanofi-Aventis and Bayer Pharma.
In 2018 Henning completed an executive MBA at the IMD in Lausanne. He holds a PhD in Chemistry with an additional degree in Molecular Genetics. Henning worked with Nobel laureate Prof. E.J. Corey at Harvard.